Loading…
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $5.6B | $408M | $208M | $217M | 15.7% | 13.0% | -2.0% |
| 2024 | $5.0B | $396M | $212M | $288M | 15.1% | 16.2% | -20.7% |
| 2023 | $4.3B | $472M | $267M | $329M | 18.8% | 9.1% | 77.4% |
| 2022 | $3.9B | $325M | $151M | $232M | 10.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 3,944.74 | 4,302.32 | 4,998.20 | 5,649.52 |
| Cost Of Revenue | 3,077.82 | 3,321.10 | 3,985.21 | 4,561.62 |
| Gross Profit | 866.92 | 981.22 | 1,012.99 | 1,087.89 |
| Operating Expense | 626.69 | 666.63 | 691.16 | 749.99 |
| Operating Income | 240.23 | 314.60 | 321.83 | 337.91 |
| EBITDA | 325.01 | 472.19 | 396.13 | 408.15 |
| EBIT | 259.57 | 409.99 | 332.63 | 337.46 |
| Pretax Income | 205.77 | 358.74 | 283.60 | 282.90 |
| Tax Provision | 55.21 | 91.65 | 71.78 | 75.31 |
| Net Income | 150.56 | 267.09 | 211.82 | 207.59 |
| Net Income Common Stockholders | 150.56 | 267.09 | 211.82 | 207.59 |
| Total Expenses | 3,704.50 | 3,987.73 | 4,676.37 | 5,311.61 |
| Interest Expense | 53.81 | 51.25 | 49.03 | 54.56 |
| Selling General And Administration | 566.12 | 607.43 | 630.25 | 682.45 |
| Normalized EBITDA | 325.01 | 472.19 | 396.13 | 408.15 |
| Normalized Income | 150.56 | 267.09 | 211.82 | 207.59 |
| Basic EPS | 0.83 | 1.49 | 1.23 | 1.28 |
| Diluted EPS | 0.83 | 1.48 | 1.23 | 1.27 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.27 | 0.26 | 0.25 | 0.27 |
| Net Income From Continuing Operation Net Minority Interest | 150.56 | 267.09 | 211.82 | 207.59 |
| Reconciled Depreciation | 65.43 | 62.20 | 63.50 | 70.69 |
| Reconciled Cost Of Revenue | 3,072.95 | 3,318.10 | 3,982.62 | 4,558.47 |
| Net Interest Income | -53.81 | -51.25 | -49.03 | -54.56 |
| Net Income From Continuing And Discontinued Operation | 150.56 | 267.09 | 211.82 | 207.59 |
| Total Operating Income As Reported | 240.23 | 314.60 | 321.83 | 337.91 |
| Diluted Average Shares | 182.07 | 180.38 | 172.84 | 163.37 |
| Basic Average Shares | 181.10 | 178.97 | 171.57 | 162.10 |
| Diluted NI Availto Com Stockholders | 150.56 | 267.09 | 211.82 | 207.59 |
| Net Income Including Noncontrolling Interests | 150.56 | 267.09 | 211.82 | 207.59 |
| Net Income Continuous Operations | 150.56 | 267.09 | 211.82 | 207.59 |
| Other Income Expense | 19.34 | 95.39 | 10.79 | -0.45 |
| Other Non Operating Income Expenses | 14.22 | 89.86 | 4.83 | -7.86 |
| Earnings From Equity Interest | 5.12 | 5.53 | 5.96 | 7.41 |
| Net Non Operating Interest Income Expense | -53.81 | -51.25 | -49.03 | -54.56 |
| Interest Expense Non Operating | 53.81 | 51.25 | 49.03 | 54.56 |
| Depreciation Amortization Depletion Income Statement | 60.56 | 59.20 | 60.91 | 67.54 |
| Depreciation And Amortization In Income Statement | 60.56 | 59.20 | 60.91 | 67.54 |
| Operating Revenue | 3,944.74 | 4,302.32 | 4,998.20 | 5,649.52 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Option Care Health, Inc.this co. | OPCH | $4.2B | 21.16 | 3.18 | 15.7% | 12.82 |
| CRISPR Therapeutics AG | CRSP | $4.9B | - | 2.53 | -30.3% | -5.64 |
| Amicus Therapeutics, Inc. | FOLD | $4.5B | - | 16.43 | -9.9% | 112.00 |
| Dianthus Therapeutics, Inc. | DNTH | $4.5B | - | 7.31 | -32.9% | -18.62 |
| Alignment Healthcare, Inc. | ALHC | $4.5B |
| - |
| 24.74 |
| -0.4% |
| 90.31 |
| Crinetics Pharmaceuticals, Inc. | CRNX | $4.0B | - | 3.70 | -46.9% | -5.94 |
| iRhythm Holdings, Inc. | IRTC | $4.0B | - | 25.53 | -29.2% | -132.48 |
| Travere Therapeutics, Inc. | TVTX | $3.7B | - | 31.75 | -22.2% | -1780.31 |
| Twist Bioscience Corporation | TWST | $3.5B | - | 7.62 | -16.4% | -30.08 |
| Peer Median | - | - | 12.02 | -25.7% | -12.28 | |